PROGNOSTIC-SIGNIFICANCE OF SINGLE CHROMOSOME-ABNORMALITIES IN PRELEUKEMIC STATES

[1] KARYOTYPIC EVOLUTION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J]. CANCER GENETICS AND CYTOGENETICS, 1985, 16 (02) : 157 - 167

[2] BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[3] RECOMMENDATIONS FOR A MORPHOLOGIC, IMMUNOLOGICAL, AND CYTOGENETIC (MIC) WORKING CLASSIFICATION OF THE PRIMARY AND THERAPY-RELATED MYELODYSPLASTIC DISORDERS - REPORT OF THE WORKSHOP HELD IN SCOTTSDALE, ARIZONA, USA, ON FEBRUARY 23-25, 1987 [J]. CANCER GENETICS AND CYTOGENETICS, 1988, 32 (01) : 1 - 10

[4] BESA E, 1985, VITAMINS CANCER HUMA, P453

[5] BESA EC, 1982, CANCER, V49, P308, DOI 10.1002/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO

[6] 2-4

[7] BESA EC, 1987, BLOOD S1, V70, pA222

[8] DANAZOL THERAPY IN MYELODYSPLASIA [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) : 58 - 60

[9] DEMORY JL, 1988, BLOOD, V72, P855

[10] DEWALD GW, 1985, BLOOD, V66, P189

[1] KARYOTYPIC EVOLUTION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES [J]. CANCER GENETICS AND CYTOGENETICS, 1985, 16 (02) : 157 - 167

[2] BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[3] RECOMMENDATIONS FOR A MORPHOLOGIC, IMMUNOLOGICAL, AND CYTOGENETIC (MIC) WORKING CLASSIFICATION OF THE PRIMARY AND THERAPY-RELATED MYELODYSPLASTIC DISORDERS - REPORT OF THE WORKSHOP HELD IN SCOTTSDALE, ARIZONA, USA, ON FEBRUARY 23-25, 1987 [J]. CANCER GENETICS AND CYTOGENETICS, 1988, 32 (01) : 1 - 10

[4] BESA E, 1985, VITAMINS CANCER HUMA, P453

[5] BESA EC, 1982, CANCER, V49, P308, DOI 10.1002/1097-0142(19820115)49:2<308::AID-CNCR2820490217>3.0.CO

[6] 2-4

[7] BESA EC, 1987, BLOOD S1, V70, pA222

[8] DANAZOL THERAPY IN MYELODYSPLASIA [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (01) : 58 - 60

[9] DEMORY JL, 1988, BLOOD, V72, P855

[10] DEWALD GW, 1985, BLOOD, V66, P189